[HTML][HTML] … of combination antiretroviral therapy in HIV-infected adults undergoing autologous or allogeneic hematopoietic cell transplant for hematologic malignancies
C Johnston, R Harrington, R Jain… - … Transplantation, 2016 - ncbi.nlm.nih.gov
… stem cells, conditioning, infusion of cells, and post-transplant … during this time until he
developed acute kidney injury on … This patient required dialysis from day +23 to+30, after which …
developed acute kidney injury on … This patient required dialysis from day +23 to+30, after which …
Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma
M Sorigue, JM Sancho, A Pineda, O Garcia, D Lopez… - Leukemia Research, 2017 - Elsevier
… BEAM (carmustine 300 mg/m 2 on day −6, etoposide and … not follow an intensive enough po
hydratation regimen when cisplatin … In most cases, RF was mild; grade 3 acute kidney injury …
hydratation regimen when cisplatin … In most cases, RF was mild; grade 3 acute kidney injury …
[PDF][PDF] … A Phase IIA Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory …
M Lill, A Steinberg, SG Zacharia, T Nguyen - classic.clinicaltrials.gov
… Carmustine would also be given on Day -6. This would be followed by etoposide and cytarabine
… reduction in tumor volume followed by acute renal failure, hyperkalemia, hypocalcemia, …
… reduction in tumor volume followed by acute renal failure, hyperkalemia, hypocalcemia, …
Guidelines for treatment of renal injury during cancer chemotherapy 2016
S Horie, M Oya, M Nangaku, Y Yasuda… - Clinical and …, 2018 - Springer
… for chronic kidney disease (CKD) and acute kidney injury (AKI)… , Japanese Society for
Dialysis Therapy, Japan Society for … searches upon establishing the following two questions: “Is …
Dialysis Therapy, Japan Society for … searches upon establishing the following two questions: “Is …
Newly established stem cell transplant program: 100 days follow-up of patients and its comparison with published Indian literature
… An 18‑gauge double‑lumen hemodialysis type intravenous catheter … Autologous hematopoietic
stem cell transplantation‑what … Autologous stem cell transplantation for multiple myeloma: …
stem cell transplantation‑what … Autologous stem cell transplantation for multiple myeloma: …
16-Conventional chemotherapy
BEN Sprangers, L Cosmai, C Porta - Onco-Nephrology, 2020 - books.google.com
… administered in the setting of acute kidney disease or CKD (… with etoposide and bleomycin,
no significant change in kidney … Carmustine is often used in combination with alkyl guanine …
no significant change in kidney … Carmustine is often used in combination with alkyl guanine …
[PDF][PDF] Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline.
J Sive, K Cuthill, H Hunter, M Kazmi… - British journal of …, 2021 - ukmyelomasociety.org.uk
… disease or with cast nephropathy-induced acute kidney injury. … Autologous stem cell
transplantation following high dose … of patients attain dialysis-independence after transplantation.…
transplantation following high dose … of patients attain dialysis-independence after transplantation.…
Onconephrology
… cancer or following hematopoietic stem cell transplantation (… kidney disease or prior episodes
of acute kidney injury (AKI) … High-dose Carboplatin/ Etoposide/Melphalan increases risk …
of acute kidney injury (AKI) … High-dose Carboplatin/ Etoposide/Melphalan increases risk …
Hematopoietic stem cell transplantation in multiple myeloma in the era of novel therapies
KA Al-Anazi - Update on Multiple Myeloma, 2018 - books.google.com
… , etoposide, cytarabine and melphalan) employed in the … therapy after autologous
HSCT for patients with MM, after … complete recovery of renal function even in dialysis-dependent …
HSCT for patients with MM, after … complete recovery of renal function even in dialysis-dependent …
Induction with MEDA regimen and consolidation with Auto‐HSCT for stage IV NKTCL patients: A prospective multicenter study
C Liu, H Ding, Q Zhu, P Liu, Y Zhu… - … Journal of Cancer, 2022 - Wiley Online Library
… using MEDA (methotrexate, etoposide, dexamethasone and … of the standard dose of BEAM
(carmustine 300 mg/m 2 day −… when they had refractory disease to MEDA or relapsed after …
(carmustine 300 mg/m 2 day −… when they had refractory disease to MEDA or relapsed after …